| |
|
|
|
|
| February 11 ,
2010 | ISSUE NUMBER 135 VOL 8 |
Research
Study Links Paxil to Breast Cancer Deaths
The popular antidepressant is associated with up to 91 percent increase in risk of death in patients undergoing tamoxifen treatment for breast cancer.
FDA
No Real New Money for Drug Regulation
Added funds for FDA to come from new user fees, largely for food and tobacco regulation.
Strategy
Ernst & Young Spotlights Pharma 3.0
The blockbuster model has been dead for a while, but pharma is just now researching new ways to reach patients. Pharm Exec interviews Carolyn Buck-Luce at Ernst & Young to learn more about the new era of pharma outreach and marketing.
Marketing
Tweeting to Your Facebook: Why Pharma is Bad at Social Media
Healthcare panel looks at why the pharmaceutical industry is struggling with a platform that’s being adopted by millions of their patients.
New & Noteworthy
First, Do No Harm...
Designing and deploying company copay offset programs without devaluing the brand. Mason Tenaglia and Christopher Meister of the Amundsen Group explain how.
|
 |
|  ADVENTRX Pharmaceuticals promoted Brian Culley to CEO and Patrick Keran to president and COO. They also appointed Odysseas D. Kostas to its board of directors.
// Viroblock SA hired Jamie Paterson as CEO.
// Poniard Pharmaceuticals appointed Ronald A. Martell CEO and Jerry McMahon chief medical officer.
// China Biologic Products added Xiangmin Cui to its board.
// Chimerix hired Gwendolyn Painter as chief medical officer.
// NeurogesX named Stephen Ghiglieri EVP, COO, and CFO. They also promoted Jeffrey Tobias to EVP, R&D and chief medical officer and Michael Markels to SVP, commercial business development.
// Amicus Therapeutics’ board elected John Crowley chairman. He is currently CEO.
// YM BioSciences added Robert Watson to its board.
// Alnara Pharma added Ashley Dombkowski to its board.
// Hemispherx Biopharma named Chris Cavalli as director of quality control.
//Hemispherx Biopharma named Robert Fidanza as director of quality assurance.
// Nektar Therapeutics added Scott Greer to its board.
// MedImmune named Peter Greenleaf president.
// Fibrocell Science hired David Pernock as CEO.
// BioClinica hired Robert Sammis as vp finance for its eClinical division.
// GlaxoSmithKline hired Philippe Fauchet to head its Japanese subsidiary.
// Lupin added Richard Zahn to its board.
// Human Genome Sciences hired Scott Habig as VP of sales.
// PharmaNet named Steve Leventer as VP, clinical research neuroscience.
// Diteba Research Labs named Sam Ricchezza as SVP of business development.
// Norwich Pharma named John Bender and James Kwon as directors of business development.
// Neurocrine Biosciences appointed William H. Rastetter to its board.
// Anthera Pharmaceuticals appointed Daniel K. Spiegelman to its board.
// Aton Pharma hired Michael H. Richardson as VP, commercial operations for the newly formed Orphan Drug Business Unit.
// Ardea Biosciences appointed Felix J. Baker to its board.
//
|
Feb 23 –25, 2010 BIO-Windhover/Pharmaceutical Strategic Outlook, New York, NY
April 12–14, 2010 19th Annual Partnerships in Clinical Trials, Orlando FL
April 20 –22, 2010 INTERPHEX, New York, NY
June 13–17, 2010 Drug Industry Association’s Annual Meeting, Washington DC |
|
|
|
 |
|
 |
|
 |
| Should HPV vaccines be mandatory for school children? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe
from this list click
here.To
ensure delivery to your Inbox, please add %%email.list%% to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
